|
|
|
|
|
FASLODEX: profile and news
Phase II Trial Explores Faslodex® After Aromatase Inhibitor 06 Mar 2006 (PRN) Analysis Demonstrates Time to Response With FASLODEX(R) ... Dec 10, 2005 Faslodex® Provides Clinical Benefit for Women with Breast Cancer ... Dec 1, 2005 Researchers probe links between gender and cancer Dec 8, 2005 AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005 AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005 Gamma-linolenic acid inhibits action of Her-2/neu, responsible for ... Nov 20, 2005 AstraZeneca Receive Highly Coveted Frost & Sullivan Award ... Sep 20, 2005 On the Mend at AstraZeneca Sep 13, 2005 New International Treatment Guidelines Verify Crucial Role of ' ... Sep 7, 2005 AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005 AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005 Faslodex® and Arimidex® Produce Similar Survival Rates Jul 14, 2005 Data Confirm Postmenopausal Women Taking Adjuvant Tamoxifen for ... Aug 4, 2005 Cancer therapy: clinical trials to trigger antihormonals market ... Jul 8, 2005 Cancer therapy: clinical trials to trigger antihormonals market ... Jul 8, 2005 Research and Markets: Providing Update Information on the Most ... Apr 27, 2005 Research and Markets: Analysis of Oncology Within Large ... Apr 27, 2005 'Zoladex(R)' (Goserelin) Adjuvant to Radiotherapy Found to Extend ... Apr 3, 2005 DATAMONITOR: New Standard in Breast Cancer Treatment Apr 19, 2005 Blocking Estrogen May Stop Lung Cancer Growth Feb 15, 2005 Blocking Estrogen Critical to Lung Cancer Survival? Feb 21, 2005 Blocking estrogen may be crucial to lung cancer survival Feb 15, 2005 Clues to why Tamoxifen does not work for some women Feb 18, 2005 Other information Indication For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Pharmacology Not Available Mechanism Of Action Not Available Drug Category Antineoplastic Agents; Antineoplastic Agents; ATC:L02BA03 Brand Names/Synonyms Faslodex; Fulvestrant; Fulvestrant [Usan] Dosage Forms SOLUTION Absorption Not Available Interactions -->Interactions for Fulvestrant: Fulvestrant is metabolized by CYP 3A4 in vitro. Clinical studies of the effect of strong CYP 3A4 inhibitors on the pharmacokinetics of fulvestrant have not been performed. Carcinogenesis, Mutagenesis and Impairment of Fertility A two-year carcinogenesis study was conducted in female and male rats, at intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days and 10 mg/rat/15 days. These doses correspond to approximately 1-, 3-, and 5-fold (in females) and 1.3-, 1.3-, and 1.6-fold (in males) the systemic exposure [AUC0-30 days]] achieved in women receiving the recommended dose of 250 mg/month. An increased incidence of benign ovarian granulosa cell tumors and testicular Leydig cell tumors was evident, in females dosed at 10 mg/rat/15 days and males dosed at 15 mg/rat/30 days, respectively. Induction of such tumors is consistent with the pharmacology-related endocrine feedback alterations in gonadotropin levels caused by an antiestrogen. Fulvestrant was not mutagenic or clastogenic in multiple in vitro tests with and without the addition of a mammalian liver metabolic activation factor (bacterial mutation assay in strains of Salmonella typhimurium and Escherichia coli, in vitro cytogenetics study in human lymphocytes, mammalian cell mutation assay in mouse lymphoma cells and in vivo micronucleus test in rat. In female rats, fulvestrant administered at doses > 0.01 mg/kg/day (approximately one-hundredth of the human recommended dose based on body surface area [BSA], for 2 weeks prior to and for 1 week following mating, caused a reduction in fertility and embryonic survival. No adverse effects on female fertility and embryonic survival were evident in female animals dosed at 0.001 mg/kg/day (approximately one-thousandth of the human dose based on BSA). Restoration of female fertility to values similar to controls was evident following a 29-day withdrawal period after dosing at 2 mg/kg/day (twice the human dose based on BSA). The effects of fulvestrant on the fertility of female rats appear to be consistent with its anti-estrogenic activity. The potential effects of fulvestrant on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides. Changes in the testes and epididymides had not recovered 20 weeks after cessation of dosing. These fulvestrant doses correspond to approximately 2-, 3-, and 3-fold the systemic exposure [AUC0-30 days] achieved in women. Pregnancy Pregnancy Category D: . In studies in female rats at doses > 0.01 mg/kg/day (IM; approximately one-hundredth of the human recommended dose based on body surface area [BSA]), fulvestrant caused a reversible reduction in female fertility, as well as effects on embryo/fetal development consistent with its anti-estrogenic activity. Fulvestrant caused an increased incidence of fetal abnormalities in rats (tarsal flexure of the hind paw at 2 mg/kg/day IM; twice the human dose on BSA) and non-ossification of the odontoid and ventral tubercle of the first cervical vertebra at doses > 0.1 mg/kg/day IM (approximately one-tenth of the human dose on BSA) when administered during the period of organogenesis. Rabbits failed to maintain pregnancy when dosed with 1 mg/kg/day fulvestrant IM (twice the human dose on BSA) during the period of organogenesis. Further, in rabbits dosed at 0.25 mg/kg/day (about one-half the human dose on BSA), increases in placental weight and post-implantation loss were observed but, there were no observed effects on fetal development. Fulvestrant was associated with an increased incidence of fetal variations in rabbits (backwards displacement of the pelvic girdle, and 27 pre-sacral vertebrae at 0.25 mg/kg/day IM; one-half the human dose on BSA) when administered during the period of organogenesis. Because pregnancy could not be maintained in the rabbit following doses of fulvestrant of 1 mg/kg/day and above, this study was inadequate to fully define the possible adverse effects on fetal development at clinically relevant exposures. Nursing Mothers Fulvestrant is found in rat milk at levels significantly higher (approximately 12-fold) than plasma after administration of 2 mg/kg. Drug exposure in rodent pups from fulvestrant-treated lactating dams was estimated as 10% of the administered dose. It is not known if fulvestrant is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions from FASLODEX in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother. Pediatric Use The safety and efficacy of FASLODEX in pediatric patients have not been established. Geriatric Use When tumor response was considered by age, objective responses were seen in 24% and 22% of patients under 65 years of age and in 16% and 11% of patients 65 years of age and older, who were treated with FASLODEX in the European and North American trials, respectively. Chemical IUPAC Name 13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol Chemical Formula C32H47F5O3S Half Life 40 days Drug Type Approved Drug # Accession No APRD00654 CAS Registry Number 129453-61-8 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |